1. Home
  2. LCFY vs CYCN Comparison

LCFY vs CYCN Comparison

Compare LCFY & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCFY
  • CYCN
  • Stock Information
  • Founded
  • LCFY 2009
  • CYCN 2018
  • Country
  • LCFY Australia
  • CYCN United States
  • Employees
  • LCFY N/A
  • CYCN N/A
  • Industry
  • LCFY
  • CYCN Biotechnology: Pharmaceutical Preparations
  • Sector
  • LCFY
  • CYCN Health Care
  • Exchange
  • LCFY Nasdaq
  • CYCN Nasdaq
  • Market Cap
  • LCFY 7.3M
  • CYCN 8.4M
  • IPO Year
  • LCFY 2022
  • CYCN N/A
  • Fundamental
  • Price
  • LCFY $7.42
  • CYCN $4.21
  • Analyst Decision
  • LCFY
  • CYCN
  • Analyst Count
  • LCFY 0
  • CYCN 0
  • Target Price
  • LCFY N/A
  • CYCN N/A
  • AVG Volume (30 Days)
  • LCFY 24.4K
  • CYCN 5.8M
  • Earning Date
  • LCFY 04-01-2025
  • CYCN 03-04-2025
  • Dividend Yield
  • LCFY N/A
  • CYCN N/A
  • EPS Growth
  • LCFY N/A
  • CYCN N/A
  • EPS
  • LCFY N/A
  • CYCN N/A
  • Revenue
  • LCFY $2,668,385.00
  • CYCN $194,000.00
  • Revenue This Year
  • LCFY N/A
  • CYCN N/A
  • Revenue Next Year
  • LCFY N/A
  • CYCN N/A
  • P/E Ratio
  • LCFY N/A
  • CYCN N/A
  • Revenue Growth
  • LCFY N/A
  • CYCN N/A
  • 52 Week Low
  • LCFY $2.20
  • CYCN $1.27
  • 52 Week High
  • LCFY $11.23
  • CYCN $9.47
  • Technical
  • Relative Strength Index (RSI)
  • LCFY 43.49
  • CYCN 58.42
  • Support Level
  • LCFY $7.10
  • CYCN $2.81
  • Resistance Level
  • LCFY $9.39
  • CYCN $6.25
  • Average True Range (ATR)
  • LCFY 0.64
  • CYCN 0.67
  • MACD
  • LCFY -0.15
  • CYCN 0.17
  • Stochastic Oscillator
  • LCFY 8.16
  • CYCN 48.35

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: